Pathogenic mechanisms underlying idiopathic pulmonary fibrosis
Sue CM, Bruno C, Andreu AL, Cargan A, Mendell JR, Tsao C-Y, et al
Beyond Weight Loss: The Broader Promise of GLP-1s Emerging clinical evidence underscores the broad therapeutic potential of GLP-1s, even extending beyond weight loss
It describes biosimilar competition as potentially arriving sooner than generic versions, says regulatory pathways for GLP-1 receptor agonist biosimilars are maturing, and notes several companies have announced development timelines targeting 2026 to 2028
Early studies indicate substantial weight loss potential , though more research is needed
Just as a side note Rifampin crushed my son when we gave it to him early in his treatments prior to treating Babesia, we discontinued Rifampin fairly quickly after speaking to a different LLMD in NY (sorry spelling isnt my thing) August 7, 2017 at 11:51 am David, Im so sorry you have a CHILD with Lyme